Attovia Therapeutics Announces First Participant Dosed in First-in-Human Phase 1 Study of ATTO-1310, its Novel Half-life Extended Anti-IL-31 ATTOBODY for the Treatment of Chronic Pruritus
January 23, 2025 07:30 ET
|
Attovia Therapeutics, Inc.
ATTO-1310 offers a potential treatment for pruritic indications like CPUO where no approved treatments exist, and the potential for best-in-disease efficacy across pruritic conditions First drug...
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis
April 10, 2024 07:00 ET
|
Sitryx Therapeutics
Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis First program from proprietary pipeline of novel immunometabolism-targeting therapies...
Vivtex and AI Proteins Enter Strategic R&D Collaboration to Develop Novel, Oral Biologic Therapies for Inflammatory Diseases
January 18, 2024 09:00 ET
|
Vivtex
Cambridge/Boston, MA, USA – 18th January 2024. Vivtex Corporation (“Vivtex”), a biotech company aiming to transform the development of oral biologic therapies for major diseases, and AI Proteins,...
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases
January 04, 2024 02:00 ET
|
Sitryx Therapeutics
Sitryx announces collaboration partner Lilly has commenced a Phase 1 study of SIT-011 for chronic autoimmune and inflammatory diseases Milestone triggers double-digit million dollar payment to...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
December 07, 2023 07:00 ET
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial
December 07, 2023 02:00 ET
|
MC2 Therapeutics
MC2 Therapeutics Announces Completion of Enrollment in MC2-25 Ph2 Chronic Kidney Disease-associated Pruritus Trial MC2-25 CKD is a first-in-class drug candidate and a potential breakthrough in the...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
November 23, 2023 07:00 ET
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus
November 23, 2023 02:00 ET
|
MC2 Therapeutics
MC2 Therapeutics Announces First Patients Enrolled in Phase 2 Proof of Concept Clinical Trial in Vulvar Lichen Sclerosus MC2-25 VLS is a first-in-class drug candidate for urea associated skin...
Global Ankylosing Spondylitis Market is Projected to Reach $7.29 Billion by 2027: Leading Players Pfizer, AbbVie, and Novartis Drive Advances in Treatment Options
October 12, 2023 07:03 ET
|
Research and Markets
Dublin, Oct. 12, 2023 (GLOBE NEWSWIRE) -- The "Ankylosing Spondylitis Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global ankylosing spondylitis...
Immune Thrombocytopenia Market Set to Reach USD 3.39 Billion by 2031: Key Trends and Advancements
October 10, 2023 04:28 ET
|
Research and Markets
Dublin, Oct. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Immune Thrombocytopenia Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.The global immune...